EMA Needs To Release DHT Guidance Now
As digital health technologies (DHTs) increasingly permeate the landscape of clinical trials, the European Medicines Agency (EMA) faces mounting...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Authority FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
As digital health technologies (DHTs) increasingly permeate the landscape of clinical trials, the European Medicines Agency (EMA) faces mounting...
ICON plc (NASDAQ: ICLR) has released its ICON Cares 2023 Report, outlining its achievements in environmental, social, and governance...
In this interview on integrating innovative digital technologies in central nervous system (CNS) trials, I engaged with Matthew Stork,...
Polo-like kinases (PLKs) are key players in cellular processes like cell cycle regulation and DNA damage response. Their dysregulation...
As a pioneer in oncological and hematological innovation, Massive Bio is showcasing its groundbreaking AI technology at the ASCO...
Lokavant, a clinical trial intelligence platform, has strengthened its team with the appointment of three new Advisory Board members...
Neurogene Inc. has reported positive initial safety and tolerability data from its ongoing Phase 1/2 gene therapy trial for...
ArteraAI has announced the validation of its AI-based digital pathology biomarker for predicting metastasis risk in prostate cancer patients...
Cybin Inc., a biopharmaceutical company specializing in psychedelic-based mental health treatments, has secured $150 million in funding to advance...
Xeris Biopharma and Beta Bionics have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize...